Unlock instant, AI-driven research and patent intelligence for your innovation.
Inhibitors against the activation of AP-1 and NFAT
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of AP-1, compound, applied in the direction of anti-inflammatory agent, digestive system, antifungal agent, etc., can solve unknown problems, etc.
Inactive Publication Date: 2005-08-24
INST OF MEDICINAL MOLECULAR DESIGN
View PDF7 Cites 1 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
However, it was not known that N-phenylsalicylamide derivatives could inhibit the activation of AP-1 or NFAT in the past
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0511] Example 1: Production of compound of compound number 1
[0516] To a benzene (8ml) solution in which O-acetylsalicylic chloride (0.20g, 1.00mmol) was dissolved, phenethylamine (0.12g, 1.00mmol) and pyridine (0.3ml) were added, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into dilute hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydroussodiumsulfate, and distilled under reduced pressure. The obtained residue was purified by silica gelcolumn chromatography (n-hexane:ethyl acetate=2:1→1:1) to obtain White crystals of the title compound (155.5 mg, 54.9%).
[0526] Example 3: Production of compound of compound number 3
[0527] Containing 5-bromosalicylic acid (109mg, 0.5mmol), 2-amino-5-(morpholino)carbonylindan (141mg, 0.5mmol), triethylamine (70μl, 0.5mmol) in dichloromethane ( 5ml) solution was added WSC·HCl (96mg, 0.5mmol), heated and stirred at 40°C for 1.5 hours. After cooling, it was diluted with ethyl acetate, washed sequentially with 2N hydrochloric acid, water, and saturated brine, dried over anhydrousmagnesiumsulfate, and concentrated, and the residue was subjected to silica gelcolumn chromatography (dichloromethane: methanol = 19:1 ) Purification to obtain the title compound as a white solid (26 mg, 11.9%).
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Property
Measurement
Unit
melting point
aaaaa
aaaaa
melting point
aaaaa
aaaaa
Login to View More
Abstract
A medicament inhibiting the activation of AP-1 which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -X-E wherein each of X and E has the same meaning as that defined above.
Description
Technical field [0001] The present invention relates to a medicine for inhibiting activator protein-1 (AP-1) or nuclear factor of activated T-cells (NFAT). Background technique [0002] N-phenyl salicylamide derivatives are described as plant growth inhibitors in the specification of U.S. Patent No. 4358443, and as medicines in the specification of European Patent No. 0221211, JP 62-99329 and U.S. Patent No. 6117859 The specification discloses that it can be used as an anti-inflammatory agent. In addition, International Publication No. 99 / 65499, International Publication No. 02 / 49632 and International Publication No. 02 / 076918 are used as NF-κB (nuclear factor-κB) inhibitors in International Publication No. 02 / 051397 No. Document is revealed as an inhibitor of cytokine production. However, it is not known that N-phenylsalicylamide derivatives can inhibit the activation of AP-1 or NFAT in the past. Summary of the invention [0003] The mechanism that people already know is that i...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
